AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00468481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drospirenone/Ethinylestradiol (Yaz)
Description: 0.020 mg ethinylestradiol with 3.0 mg drospirenone
Study NCT02242682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child passenger safety video
Study NCT02582892 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vit D
Description: 20 mg/day
Study NCT02772211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals.
Study NCT02772211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.~After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals.
Study NCT02772211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day
Study NCT02772211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks \[2\] in the following manner:~1. Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.~2. Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day~3. Week 7: Day 43-49 - 750mg/d, three pills per day~4. Weeks 8-11: Days 50-77 - 1000mg/d four pills per day
Study NCT04173156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Labrida Bioclean
Description: The brush bristles of the test device (Labrida BioClean®, LABRIDA, Oslo, Norway) are made of the biopolymer chitosan
Study NCT04173156 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gracey Periodontal curettes
Description: Regular commercially available area specific and medical grade steel Gracey periodontal curettes
Study NCT03185195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125 Oral Tablet
Description: Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
Study NCT03185195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AQX-1125 IV
Description: Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
Study NCT03185195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-AQX-1125 Oral Solution
Description: Part 1: Subjects will receive a single oral dose of AQX-1125 followed by \[14C\]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive \[14C\]-AQX-1125 oral solution.
Study NCT00813254 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
Study NCT00077298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00077298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00077298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00077298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03408301 — intervention group
Intervention type: PROCEDURE
Intervention: Tourniquet deflation
Description: Tourniquet deflation
Study NCT02812069 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ThermaZone® Device
Description: The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
Study NCT02284061 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physical activities adapted to children
Study NCT02284061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activities adapted to children
Study NCT01386385 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-conformal RT
Study NCT01386385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01386385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT01386385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01386385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01386385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01386385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT01386385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT01386385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT00103246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silicon phthalocyanine 4
Description: Participants receive topical silicon phthalocyanine 4 (Pc 4). One hour later, participants undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
Study NCT02527798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Cohort 1
Description: furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
Study NCT02527798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Cohort 2
Description: furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
Study NCT02527798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Cohort 3
Description: furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
Study NCT02527798 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar water will be administered in a equivalent volume as drug intervention.
Study NCT04704375 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bio Electro-Magnetic Regulation (BEMER) Therapy
Description: BEMER is a therapeutic modality that deploys a biorhythmically defined stimulus through Pulsed Electromagnetic Field (PEMF). This stimulus has a targeted effect on the microvasculature, and the primary effect is an improvement in tissue microcirculation. The positive effects of vasomotion on the microcirculation has been shown to result in significant increases in arteriovenous oxygen difference, number of open capillaries, arteriolar and venular flow volume, and flow rate of red blood cells in the microvasculature. Therefore, BEMER can potentially be used in the treatment of LBP by improving microcirculation in muscular tissue.
Study NCT04704375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT (osteopathic manipulative treatment)
Description: i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
Study NCT04704375 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OMT (osteopathic manipulative treatment)
Description: i. OMT Myofascial release (MFR), soft tissue (ST) release, muscle energy (ME), counterstrain (CS), and balanced ligamentous tension (BLT) technique.
Study NCT04704375 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Light touch
Description: Treaters will place their hands lightly on the subject's lumbar paraspinal muscles in the supine and prone positions in the same area as where one would place your hands for lumbar MFR technique for the same amount of time as it would take to perform MFR in this area (approximately 5 minutes). However, no lifting or action will be done. In addition, the subject will lie down on the BEMER mat (as they would do during a BEMER session), but the device will not be activated.
Study NCT00605436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative yoga therapy
Description: 3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
Study NCT01368705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard protein delivery
Description: Protein delivery of 1.5 g/kg/day.
Study NCT01368705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 1 (2.2g/kg/day)
Description: protein delivery of 2.2g/kg/day
Study NCT01368705 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 2 (3.0 g/kg/day)
Description: protein delivery of 3.0 g/kg/day
Study NCT01348620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)
Description: Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson \& Johnson Medical Spa)
Study NCT01348620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four port laparoscopic cholecystectomy surgery
Description: Four port laparoscopic cholecystectomy surgery
Study NCT00074282 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00074282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00074282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentostatin
Study NCT00074282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study NCT00975117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo tablet (Orally administered) twice a day, for 12 weeks.
Study NCT00975117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermotrend
Description: One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
Study NCT00639717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stem cell transplant
Description: reduced intensity, matched unrelated donor stem cell transplant
Study NCT00639717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus (standard GVHD prophylaxis)
Description: Tacrolimus(or cyclosporine when necessary)~Tacrolimus will begin on day -3, IV or oral.~Target trough level for tacrolimus is 8-12 ng/ml.~In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
Study NCT00639717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate (standard GVHD prophylaxis)
Description: Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
Study NCT00639717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
Study NCT00639717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxsalen
Description: Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.~On day +70 post transplant ECP frequency will be given every other week.~On day +100 post transplant ECP will be given monthly until day +180 and stopped.
Study NCT01756092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Graft
Description: Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
Study NCT01759589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: 1 mg/kg propofol IV (over 15 sec) during anesthesia induction
Study NCT01759589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil and propofol
Description: 1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
Study NCT01759589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
Study NCT05450848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataXRT
Description: StrataXRT is a flexible wound dressing for the prevention and treatment of radiation dermatitis. It is in the form of a gel which, when applied, creates a protective film that maintains skin integrity. The product is used to relieve low grade inflammatory radiation changes such as dry, itching, flaking, peeling and irritated skin. For more severe inflammatory changes with open wound components, StrataXRT reduces pain, redness and heat and helps soothe the exposed skin areas. StrataXRT can be applied where skin integrity has been compromised and may also be used in conjunction with other adjunctive treatments to improve overall results. StrataXRT contains Polydimethylsiloxanes, Siloxanes and Alkylmethyl Silicones and is transparent and odourless. It does not contain alcohols, parabens or fragrances. StrataXRT can be used with or without a secondary protective dressing. It is suitable for children and people with sensitive skin.
Study NCT03061136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Study NCT05450848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sorbolene
Description: Aqueous cream (moisturizer) that soothes itchiness and dryness of the skin, and aids skin hydration. It is non-greasy, fragrance free, colour free, GMO free, paraben free and pH balanced.
Study NCT02891187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone follow-up
Description: Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
Study NCT02891187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Clinic Visits
Description: Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
Study NCT04250649 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous tissue disinfection
Description: Skin and subcutaneous incision (up to the muscular fascia) with superficial blade scalpel, disinfection of the subcutaneous tissue with 3cc of Betadine solution, placement of the retractors, dissection and development of the delto-pectoral interval with deep blade scalpel.~When the joint is opened, bacteriological smears are taken from 5 sites in the two groups. 1) exposed subcutaneous tissue, 2) surgeon's gloves (distal end of fingers), 3) superficial blade, 4) deep blade, 5) retractors.~The rest of the shoulder surgery procedure does not differ from what is commonly performed.~The samples are sent to bacteriology for bacterial culture. Anaerobic research is done specifically for P. acnes. The results are considered negative after 10 days.
Study NCT05225493 — intervention group
Intervention type: BEHAVIORAL
Intervention: Peer to peer feedback
Description: HIV experts contact non-HIV specialised treating physicians on individual patient care to recommend HIV testing
Study NCT05225493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HIV rapid test
Description: Free HIV rapid tests are provided to non-HIV specialised treating physicians to use in individual patient care in patients at risk of HIV
Study NCT03061136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03839251 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: abilify maintena
Description: aripiprazole 400mg or 300mg, IM, Once a month
Study NCT04443023 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: chosen TAVI valve
Description: chosen TAVI valve
Study NCT02947126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Inhaled 7% Hypertonic saline
Study NCT02947126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotonic Saline
Description: Inhaled 0.9% Isotonic saline
Study NCT02947126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indium-DTPA
Description: Inhaled Indium 111 DTPA
Study NCT02947126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Sulfur Colloid
Description: Inhaled Technetium99m sulfur colloid
Study NCT02789280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities.
Description: Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated
Study NCT02789280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait list
Description: will receive the behavioral activation condition after one week of completing baseline assessment.
Study NCT03100617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial caregiver intervention
Description: Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
Study NCT03624101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta
Description: CFTR modulator
Study NCT03624101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: symdeko/Trikafta
Description: CFTR modulator
Study NCT03624101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor/Trikafta
Description: CFTR modulator
Study NCT01024569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Recovery Action Planning (WRAP)
Description: WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
Study NCT01588184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
Study NCT02660957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-determination smoking cessation
Description: a self-help quitting leaflet plus a series of brief interventions using the AWARD model
Study NCT02660957 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: suggest a healthy life style as a placebo comparator
Study NCT05445362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diode laser disinfection
Description: - Disinfection with parameter of Power: 1.5 watt, Mode: pulse: SP: Ton=10ms; Toff10ms 50Hz (50% pulse mode), for 5 seconds in spiral movement in apical to coronal direction no stop with non-initiated endodontic tip 200 micron diameter and 15 mm length three times. Irrigation with NaOCl, irradiation with the laser, then irrigation with E.D.T.A and irradiation with the laser, for three times then final rinse with distilled water with paper point dryness in between irrigations.